Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
|Articles|January 11, 2011
Strategies for Treating High Blood Pressure and High Cholesterol
Video explores current options for managing hypertension and atherosclerosis.
Advertisement
In this UCSD TV video, UCSF's Robert Baron, MD, Associate Dean for Graduate and Continuing Medical Education, Vice Chief of the Division of General Internal Medicine, and director of the UCSF Weight Management Program, explores the current strategies for treatment of high blood pressure and high cholesterol.
Advertisement
Related to this article
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
The HCPFive: Top News for Healthcare Providers from the Week of 10/18
3
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
4
Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant
5